NAX 035
Alternative Names: Berberine Derivative - AROMICS; NAX-035Latest Information Update: 03 Oct 2023
At a glance
- Originator AROMICS; Fondazione IRCCS Istituto Nazionale dei Tumori; Naxospharma
- Developer Aesis Therapeutics; AROMICS; Fondazione IRCCS Istituto Nazionale dei Tumori; Naxospharma
- Class Antineoplastics; Berberine alkaloids; Small molecules
- Mechanism of Action Thymidylate synthase expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Malignant-mesothelioma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
Most Recent Events
- 26 Sep 2023 Naxospharma plans a clinical trial for Malignant mesothelioma (PO) (AROMICS website, September 2023)
- 20 Sep 2023 NAX 035 is available for licensing as of 20 Sep 2023. https://aromics.es/en/section/research
- 15 May 2016 Preclinical trials in Malignant mesothelioma in Italy (Intraperitoneal)